FIELD: medicine.
SUBSTANCE: method involves applying Sarsasapogenin in combination with one or several compounds taken from group consisting of Smilagen and Anzurogenin-D, for preparing composition for treating Parkinson disease or for treating postural hypotension, autism, chronic fatigue syndrome, heavy myasthenia gravis, Lambert-Eaton disease, Gulf War Syndrome and syndrome caused by professional contact with organophosphorous compounds. Sarsasapogenin selectively increases muscarinic receptors M1 activity, contributing to stimulating synaptic transmission, without М2 receptors activity being influenced (which evoke negative feedback and muscarinic transmission interruption).
EFFECT: enhanced effectiveness of treatment.
3 cl, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| STEROID SAPOGENIN AND THEIR DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | 1999 |
|
RU2242978C2 |
| DERIVATIVES OF 5B-SAPOGENIN AND PSEUDO SAPOGENIN AND APPLICATION FOR DEMENTIA MEDICAL TREATMENT | 2000 |
|
RU2325396C2 |
| DERIVATIVES OF SAPOGENIN, THEIR SYNTHESIS, USING AND METHOD BASED ON THEIR USING | 2002 |
|
RU2311423C2 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL AGENTS BASED ON THEREOF | 1999 |
|
RU2278111C2 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1999 |
|
RU2230740C2 |
| THERAPEUTIC METHODS AND APPLICATIONS OF SAPOGENINS AND DERIVATIVES THEREOF | 2003 |
|
RU2332999C2 |
| APPLICATION OF N-DISMETILKLOSAPINE FOR HUMAN NEUROPSYCHIATRIC DISEASES TREATMENT | 2004 |
|
RU2336879C2 |
| 5-HT RECEPTOR AGONIST COMPOUNDS FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2569056C2 |
| TREATMENT OF OVERACTIVE BLADDER SYNDROME | 2022 |
|
RU2792534C1 |
| AGONISTS OF ALPHA-2B OR 2B/2C ADRENORECEPTORS FOR NEURODEGENERATIVE DISEASES TREATMENT | 2003 |
|
RU2330649C2 |
